Therefore, selective XO inhibitors such as allopurinol and febuxostat, which are used to lower uric acid level and reduce the risk of a gout flare in gout patients, may represent new drug candidates for the treatment of DM-related organ injury because of their ROS-lowering effects. This evidence concerns the gene XDH and gout.